Advanced searches left 3/3

Cell Carcinoma - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 January 2023

* If you want to update the article please login/register

Immunophenotyping in Metastatic Renal Cell Carcinoma Patients Receiving Ablative Therapy

In metastatic renal cell carcinoma patients, pre- and post-treatment immune markers and peripheral blood mononuclear cell characteristics are similar. Patients being treated with stereotactic body radiation therapy (versus percutaneous cryoablation), as well as immunotherapy are also undergoing immunotherapy. Specifically, analyze the effect of post-treatment immune markers and PBMC characteristics on distant disease progression in metastatic RCC patients.

Source link: https://clinicaltrials.gov/ct2/show/NCT05112627


Phase II Study of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Background: Pancreatic Acinar Cell Carcinoma is a rare pancreatic tumor that accounts for 0. 59 percent of all pancreatic malignancies. Mutations in DNA repair genes have been shown to identify subgroups of cancer patients with specific vulnerability to DNA damage response inhibitors in both ovarian and prostate cancer patients. We predict that PACC will be vulnerable to PARP inhibition with olaparib as PACC has multiple signs of HRR deficiency. Both subjects will take olaparib by mouth twice a day for up to two years or until disease progression or intolerable side effects.

Source link: https://clinicaltrials.gov/ct2/show/NCT05286827


LCCC 1608 - HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi

RATIONALE FOR RESEARCH The Rift Valley of Africa is Africa's 'hot spot' for ESCC, but little is known about the disease's etiology in Sub-Saharan Africa. ESCC is Malawi's third most common cancer worldwide behind Kaposi sarcoma and cervical carcinoma. ESCC has the highest prevalence in Malawi among cancers that are not strictly HIV-related. The ESCC burden reported in the national cancer registry is underestimate, considering that many cases go undiagnosed and unregistered. This knowledge gap is a significant barrier to public health education efforts. Secondly, our report will include a prospective clinical follow-up of suspected ESCC cases as they receive medical attention under local circumstances to obtain accurate survival statistics. We intend to collaborate with other ESCC researchers in eastern and southern Africa to harmonize data processing and help establish a regional consortium in which Malawi can be a founding member and active participant. Secondary Objective: Identify common genetic and epigenetic variations in germline and somatic DNA that are associated with ESCC evolution. Analysis The sample size will include 300 ESCC cases and 300 controls; 66-68 case control pairs will be recruited per year, over three years, with a response rate of 75% in the endoscopy clinic. Using alpha level 0. 05 with higher precision for higher control exposure rates and odds ratios, 300 case-control pairs estimated statistical rigor for an exposure with control population prevalence of 10% and OR 2. 0 is 81%, with greater vigor for higher control exposure rates and odds ratios.

Source link: https://clinicaltrials.gov/ct2/show/NCT03160209


Avelumab, Palbociclib and Axitinib in in Treatment Naive Metastatic Clear Cell Renal Cell Carcinoma.

This research examines an investigational drug combination that has not been approved by the FDA for the treatment of advanced clear cell renal cell carcinoma, but the combination of axitinib and avelumab has been approved for use in advanced clear cell renal cell carcinoma therapy. Palbociclib is a CDK inhibitor that prevents the proliferation of new cancer cells by blocking how a phosphate molecule is added to a key regulatory protein, retinoblastoma.

Source link: https://clinicaltrials.gov/ct2/show/NCT05176288


A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma

This is a two-arm, non-randomized phase 1/1B study aimed at determining the efficacy and efficiency of abemaciclib alone and abemaciclib plus MK-6482 in patients with advanced refractory clear-cell renal cell carcinoma. A Phase I clinical trial evaluates the safety of an investigational drug or drug combination as well as determining the correct dose of the investigational drug or drug mixture to use for further research. The U. S. Food and Drug Administration hasn't provided either abemaciclib or MK-682 for renal cancer, but abemaciclib has been licensed to treat other forms of cancer. When the cells start to grow and divide, Abemaciclib blocks these proteins, and other cancers have been shown to slow down cancer cell formation and division, causing cancer cells to become inactive or even die. This review is looking at two specific therapies: Arm 1 - abemaciclib alone: To determine the response rate of abemaciclib alone in patients with advanced ccRCC Arm 2 - combination therapy of abemaciclib and MK-6482 in combination. Following the study's success, the researcher may recommend that participants return to clinic for additional tumor tests or his/her staff will contact participants every 6 months to track their health status and find out about any anticancer therapies that may have started after study participants.

Source link: https://clinicaltrials.gov/ct2/show/NCT04627064


A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

As determined by an independent central review, magrolimab can be used to determine progression-free life with magrolimab in combination with peterolizumab + 5-FU + platinum. Phase 2 Cohorts 2 and 3: To determine the effect of magrolimab, pemolizumab, and magrolimab in combination with docetaxel, as determined by the investigator-assessed objective response rate.

Source link: https://clinicaltrials.gov/ct2/show/NCT04854499


Post-Operative Radiotherapy De-Escalation of Negative Nodal Regions in Head and Neck Squamous Cell Carcinoma

According to tumor latency, nodal status, and the laterality of nodal dissection, 57 head and neck squamous cell carcinoma cases suitable for post-operative radiotherapy will be recruited and treated. If ipsilateral N positive and tumor were not well lateralized, ipsilateral nodal regions would be radioradiated with conventional doses, although the contralateral nodal irradiation dose equivalent will be reduced to 40 Gy dose equivalent. If one sided N-positive, the tumor's latency of the tumor will be determined, and the contralateral nodal irradiation will be skipped. The positive side nodal regions will be irradiated with standard doses, while the contralateral nodal region will be reduced to 40 Gy dose equivalents.

Source link: https://clinicaltrials.gov/ct2/show/NCT05650034

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions